Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bitcoin ETF (BITU) vs Johnson & Johnson (JNJ) Price & Performance

ProShares Ultra Bitcoin ETFTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bitcoin ETF vs Johnson & Johnson — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.87, while Johnson & Johnson trades at $252.91 (market cap $611.07B). The key difference: Johnson & Johnson pays a 2.11% dividend while ProShares Ultra Bitcoin ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.

BITUJNJ
Sector
Leveraged / InverseHealth
52-Week High
$64.41$267.24
52-Week Low
$8.12$155.17
Market Cap
$611.07B
Volume
6,156,228
Enterprise Value
$644.01B
Dividend Yield
2.11%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bitcoin ETF

BITU trades at $9.01, down 5.16% over 24 hours amid bearish technical signals. The stock shows weak momentum with moving averages indicating a downtrend and oscillators neutral. Recent news highlights concerns over its leveraged ETF structure causing underperformance versus Bitcoin. The company pays small dividends but key valuation and profitability ratios are unavailable.

Outlook remains cautious due to structural decay risks and negative sentiment. Investment opportunity is limited to speculative traders during sustained bull markets, but risks of volatility decay and investor selling pressure outweigh potential gains in the near term.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $257.77, up 0.31% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $94.19B, net income margin of 21.83%, and consistent earnings beats. Recent dividend declaration of $1.34 and positive analyst coverage with 52.5% buy ratings reinforce confidence. The current price sits near pivot point resistance at $258, with technical indicators showing bullish momentum from moving averages.

JNJ presents a compelling long-term investment with stable cash flows, strong profitability metrics, and defensive healthcare positioning. Upside potential exists toward the $281 consensus price target, though risks include rising debt-to-asset ratio (24.06% in 2025) and patent expiration headwinds. The stock's 60+ year dividend growth history provides income stability amid market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Bitcoin ETF

BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.

Read more on BITU

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ